Skip to main content

Vimpat FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 16, 2021.

FDA Approved: Yes (First approved October 28, 2008)
Brand name: Vimpat
Generic name: lacosamide
Dosage form: Tablets, Injection, Oral Solution
Company: UCB, Inc.
Treatment for: Seizures

Vimpat (lacosamide) is an anti-convulsant indicated for the treatment of partial-onset seizures in patients 1 month of age and older, and the adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.

Development timeline for Vimpat

DateArticle
Nov 17, 2020Approval Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy
Oct 29, 2008Approval UCB's Vimpat Approved By U.S. FDA As Adjunctive Therapy for Partial Onset Seizures in Adults
Jul 29, 2008UCB Receives Not-Approvable Letter from FDA for Lacosamide for Diabetic Neuropathic Pain
Nov 29, 2007UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
Nov 28, 2007UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain

See also

Vimpat (lacosamide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer